Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study

British Journal of Clinical Pharmacology

Volumn 80, Issue 5, 2015, Pages 1051-1063

  Dong, Jennifer Q ^a   Rossulek, Michelle ^a   Somayaji, Veena R ^a   Baltrukonis, Daniel ^a   Liang, Yali ^a   Hudson, Krischan ^a   Hernandez Illas, Martha ^b   Calle, Roberto A ^a  

^a PFIZER INC   (United States)

^b MRA Clinical Research   (United States)

Author keywords

FGF21; pharmacodynamics; pharmacokinetics; T2DM

Indexed keywords

ANTIDIABETIC AGENT; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PF 05231023; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; FIBROBLAST GROWTH FACTOR; MONOCLONAL ANTIBODY; PF-05231023;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTACT DERMATITIS; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DIET; DIZZINESS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; NO-OBSERVED-ADVERSE-EFFECT LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; VOLUME OF DISTRIBUTION AT STEADY-STATE; VOMITING; AGONISTS; BLOOD; DOSE RESPONSE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED;

ADMINISTRATION, INTRAVENOUS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; TRIGLYCERIDES;

EID: 84946496130     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12676     Document Type: Article

References (20)

1. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR,. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12.
2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
4. Gaster B, Hirsch IB,. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med 1998; 158: 134-40.
5. Resnick HE, Bardsley J, Foster GL, Ratner RE,. Achievement of American Diabetes Association clinical practice recommendations among US adults with diabetes, 1999-2002: the National Health and Nutrition examination survey. Diabetes Care 2006; 29: 531-7.
6. Saydah SH, Fradkin J, Cowie CC,. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-42.
7. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G,. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43.
8. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB,. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115: 1627-35.
9. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E,. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 2009; 150: 4931-40.
10. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB, Etgen GJ,. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007; 148: 774-81.
11. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA, Tripathy D,. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009; 32: 1542-6.
12. Gimeno RE, Moller DE,. FGF21-based pharmacotherapy-potential utility for metabolic disorders. Trends Endocrinol Metab 2014; 25: 303-11.
13. Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, Kharitonenkov A, Bumol T, Schilske HK, Moller DE,. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 2013; 18: 333-40.
14. Huang J, Ishino T, Chen G, Rolzin P, Osothprarop TF, Retting K, Li L, Jin P, Martin MJ, Huyghe B, Talukdar S, Bradshow CW, Palanki M, Violand BN, Woodnutt G, Lappe RW, Ogilvie K, Levin N,. Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody. J Pharmacol Exp Ther 2013; 346: 270-80.
15. Weng Y, Chabot J, Bernardo B, Yan Q, Zhu Y, Brenner MB, Vage C, Logan A, Calle R, Talukdar S,. Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice. PLoS One 2015; 10: e0119104.
16. Giragossian C, Vage C, Li J, Pelletier K, Piche-Nicholas N, Rajadhyaksha M, Liras J, Logan A, Calle RA, Weng Y,. Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate. Drug Metab Dispos 2015; 43: 803-11.
17. Jusko WJ, Ko HC,. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 1994; 56: 406-19.
18. Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, Hurh E, Gibbs MA,. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet 2011; 50: 131-42.
19. Xue L, Rup B,. Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics. AAPS J 2013; 15: 893-6.
20. Xue L, Fiscella M, Rajadhyaksha M, Goyal J, Holland C, Gorovits B, Morimoto A,. Pre-existing biotherapeutic-reactive antibodies: survey results within the American Association of Pharmaceutical Sciences. AAPS J 2013; 15: 852-5.